By CCN.com: Biopharmaceutical company ARCA biopharma (NASDAQ: ABIO) led the stock market yesterday with a mind-blowing 98.64% gain on the day. The ABIO stock price rocketed following an announcement that the company had a critical research paper published in JACC: Heart Failure, part of the Journal of American College of Cardiology. Why Is This Publication Important? ARCA biopharma is currently working on treating cardiovascular diseases with genetically-targeted therapies. Their lead product candidate is GencaroTM (bucindolol hydrochloride), a beta blocker and mild vasodilator that could potentially treat atrial fibrillation in heart failure patients. Because ARCA is a pharma company, the success
The post Why Pharma Stock ABIO Skyrocketed a Mind-Blowing 100% appeared first on CCN
* First published on ccn.com
